HK/China Healthcare Analyst (ex-Fosun Pharma)

Xinyao (Criss) Wang

Over 15 years' experience in both finance and healthcare, covering clinic operations, investment and equity research in both China and overseas.

Pre-IPO Hong Kong Medical Consultants - Promising Future Despite Short-Term Declining Profitability

Chongqing Zhifei Biological Products- Promising Future After Successful Renewal of Contract with MSD

Hygeia Healthcare Group (6078 HK) - Good Business Model with Large Market Potential

Pre-IPO Yidu Tech Inc - The Future Performance Is Worth Looking Forward To

Pre-IPO Bio-Thera Solutions - Insights on Pipeline and the Competitive Landscape

Pre-IPO MicroPort CardioFlow - A Better Candidate of the TAVR Market in China?

Gravity Works As WeWork Doesn't; Now Plan B

Bifurcated Chinese Express Market Developing

Equity Capital Markets

Gracell Biotechnologies Inc / Equity Capital Markets

<p><a href="https://www.smartkarma.com/entities/gracell-biotechnologies-inc" target="_blank" data-smartkarma-citation="entities:31108:1" rel="noopener">Gracell Biotechnologies Inc (GRCL US)</a>, a global clinical-stage biopharmaceutical company dedicated to discovering and developing breakthrough cell therapies, was listed on Nasdaq. On its first day of trading, Gracell's shares jumped by about 32%, with a market value of $1.643 billion. Since the establishment, Gracell has had a clear listing schedule and plans to go public in early 2021. Gracell chooses to list on NASDAQ mainly because it believes that international capital market would be more suitable for the Company's development, which is conducive to future cooperation with American research institutes and enterprises, license-in or acquisition. It is also worth mention that although there are many pharmaceutical companies in the CAR-T field, the limitations of the therapies are still very prominent. So how is Gracell different from others? Could it become a game changer?</p>

Gracell Biotechnologies Inc (GRCL US), a global clinical-stage biopharmaceutical company dedicated to discovering and developing breakthrough cell therapies, was listed on Nasdaq. On its first day of trading, Gracell's shares jumped by about 32%, with a market value of $1.643 billion. Since the establishment, Gracell has had a clear listing schedule and plans to go public in early 2021. Gracell chooses to list on NASDAQ mainly because it believes that international capital market would be more suitable for the Company's development, which is conducive to future cooperation with American research institutes and enterprises, license-in or acquisition. It is also worth mention that although there are many pharmaceutical companies in the CAR-T field, the limitations of the therapies are still very prominent. So how is Gracell different from others? Could it become a game changer?

Gracell Biotechnologies (GRCL.US) - Could It Become a Game Changer?